Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia.

Chakraborty, Sandip N

Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia. [electronic resource] - Genes & cancer May 2016 - 201-208 p. digital

Publication Type: Journal Article

1947-6019

10.18632/genesandcancer.111 doi